Table 3. Multivariable Cox regression analysis of KLK4 mRNA expression levels and patients survival in advanced high-grade ovarian cancer (FIGO III/IV).
| Clinical parameters | OS | PFS | ||||
|---|---|---|---|---|---|---|
| Noa | HR (95% CI) b | p | No a | HR (95% CI) b | p | |
| Age | 0.470 | 0.733 | ||||
| ≤ 60 years | 47 | 1 | 41 | 1 | ||
| > 60 years | 69 | 1.22 (0.72–2.07) | 60 | 0.92 (0.56–1.51) | ||
| Residual tumor mass | < 0.001 | 0.002 | ||||
| 0 mm | 63 | 1 | 58 | 1 | ||
| > 0 mm | 53 | 3.58 (1.90–6.74) | 43 | 2.36 (1.38–4.05) | ||
| Ascitic fluid volume | 0.911 | 0.474 | ||||
| ≤ 500 ml | 71 | 1 | 63 | 1 | ||
| > 500 ml | 45 | 1.03 (0.58–1.86) | 38 | 1.22 (0.71–2.10) | ||
| KLK4 mRNA c | 0.006 | 0.284 | ||||
| low | 58 | 1 | 52 | 1 | ||
| high | 58 | 2.31 (1.27–4.20) | 49 | 1.32(0.79–2.20) | ||
The biological marker KLK4 mRNA was added to the base model of clinical parameters: age, residual tumor mass, and ascites fluid volume. Significant p-values (p < 0.05) are indicated in bold.
a Number of patients;
b HR: hazard ratio (CI: confidence interval) of multivariable Cox regression analysis;
c Dichotomized into low and high levels by median.